局限期小细胞肺癌治疗新格局： 从传统放化疗到精准治疗的新进展.
Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive malignancy with a poor prognosis. For a long time, the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy; however, most patients still face recurrence...
| Published in: | Chinese Journal of Lung Cancer Vol. 29; no. 2; pp. 150 - 159 |
|---|---|
| Main Authors: | , , , |
| Format: | research systematic review tables/charts Journal Article |
| Published: |
Chinese Journal of Lung Cancer
Feb2026
|
| Online Access: | View this record in EBSCOhost |